AmCham EU responds to impact assessment on medicines for children and rare diseases

AmCham EU responded to the recent inception impact assessment on the revision of the EU legislation on medicines for children and rare diseases. In the response we encouraged the European Commission to protect frameworks that stimulate R&D, to build on the EU’s strengths and to incorporate learning from other regions. Read the full response here.